Invited Commentary

Commentary on “Use of Rheumatologic Testing in Patients Who Eventually Receive a Diagnosis of Rheumatoid Arthritis”

Authors: Kam A. Newman, MD, MohamadOmid Edrissian, MD

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disorder of unknown etiology, for which delay in diagnosis and treatment may cause irreversible structural joint damage in affected individuals. A large body of evidence supports that early diagnosis and aggressive treatment of RA have a fundamental role in the prevention of irreversible joint damage and consequent disability.
Posted in: Rheumatology and Orthopedics7 Rheumatoid Arthritis2

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Singh DK, Badwal J, Vankina R, et al. Use of rheumatologic testing in patients who eventually receive a diagnosis of rheumatoid arthritis. South Med J 2019;112:535-538.
2. Aletaha D, Eberl G, Nell VP, et al. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004;63:1269-1275.
3. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-914.
4. Lee D, Schur P. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-874.